Short answer
As of October 2026, an in-person medical weight loss clinic can advertise its program on Meta and Google without certification, and may name semaglutide in US Google ad text and on its page, but not keyword-target it. MedScale Health, a paid ads agency for US telehealth brands and clinics, pre-clears clinic creative against Meta's health and personal attributes standards before spend. On Meta, only telehealth providers, pharmacies and manufacturers can be authorized to promote the drug; ads target adults, and inferiority statements, pinched-fat close-ups and "tired of the weight?" hooks fail.
What does this mean for a medical weight loss clinic?
- Lead with the program and the supervision. On Google, an in-person clinic may name the drug in US ad text and on its page without certification since October 29, 2025, but needs certification to keyword-target drug names. On Meta, promoting the drug needs LegitScript and Meta's authorization, which Meta grants only to online pharmacies, telehealth providers and manufacturers, so an in-person-only clinic leads with the program.
- Target adults only on every platform. Meta's health and wellness standard requires it for weight-loss advertising, and a mis-set ad set fails on its own.
- Meta lets adults-only weight-loss ads show the product's impact, and since July 22, 2026 it no longer bans before-and-after comparisons for weight loss. Pinched-fat close-ups, inferiority statements, timed promises without a qualifier and "you" hooks still fail. MedScale's own ads skip before-and-after entirely; that is MedScale's rule, not Meta's.
- If your program includes compounded semaglutide or tirzepatide, say "compounded, not FDA-approved" wherever it is named, and never imply it is the same as the branded drug.
- Pixel events named after the drug pull the account into restricted delivery. Name them generically.
MedScale Health, a paid acquisition agency for telehealth brands and clinics, treats medical weight loss as the highest-intent search demand in local healthcare and the fastest way to get an ad account restricted when the creative is built like a supplement ad. The Meta and Google rules on this page are the ones that produce those restrictions. Before a clinic spends more, MedScale's free Growth Audit marks which of its live ads and pages those rules would flag and which channels it can run today. MedScale's answers are marketing guidance for healthcare operators, not medical or legal advice, and platform policies change: check the sources listed at the end before acting on any specific rule.
What are Meta's rules for weight loss clinic ads?
Meta applies three standards and one age rule to weight loss clinic ads. Meta's health and wellness standard requires weight-loss advertising to be targeted to people 18 or older, prohibits statements of inferiority about physical appearance, prohibits weight-loss close-ups that pinch fat, and treats promises of specific outcomes in a set time without disclaimers or qualifiers as clickbait. It lets adults-only weight-loss ads show people using the product or service, its impact, and the time taken to see results, and since July 22, 2026 it no longer bans before-and-after comparisons for weight loss. The personal attributes standard prohibits copy that asserts or implies a viewer's medical condition or physical characteristics; Meta's own examples make the point that a program can be described but the reader cannot be diagnosed. The drugs and pharmaceuticals standard applies the moment an ad or a page promotes a prescription medication: LegitScript certification and Meta's authorization are required, and the advertising must be to adults. Meta grants that authorization only to online pharmacies, telehealth providers and pharmaceutical manufacturers, so an in-person-only clinic has no route to Meta ads that promote the drug.
A clinic that only ever advertises its supervised program can run under the health and wellness and personal attributes standards without certification. The drugs and pharmaceuticals standard is triggered by naming the drug, by a landing page that lists medications with prices, or by a pixel that reports a medication event. Clinics are usually restricted by the page, not the ad, which is why MedScale reviews the landing page with every clinic ad.
Can a weight loss clinic name semaglutide in Google Ads?
Yes, in ad text and on the landing page, but not as a keyword without certification. Google's restricted drug terms policy for the United States changed on October 29, 2025. It now says advertisers do not need certification to use prescription drug terms in ads and landing pages, but must be certified to keyword-target those terms, and that online pharmacies, telemedicine providers and pharmaceutical manufacturers must be certified regardless. For an in-person clinic, that means semaglutide or tirzepatide can appear in ad text and on the landing page, while "semaglutide" as a keyword still needs certification. A clinic that prescribes by telehealth or ships medication is a telemedicine provider or pharmacy in Google's terms, and needs LegitScript first, then Google's certification.
Program and clinic intent is open: "medical weight loss clinic near me", "GLP-1 program", "physician supervised weight loss". Those campaigns are where a clinic starts, with location-level budgets and call tracking tied to the booked consult. Misspellings and spacing tricks to get drug names past the keyword rule are circumvention, and circumvention is the label that ends accounts rather than ads. MedScale starts an uncertified clinic on those program and clinic campaigns.
Which compounded semaglutide and tirzepatide claims draw FDA warning letters?
Sameness claims and claims that hide who compounded the drug draw the letters. On March 3, 2026 the FDA announced warning letters to 30 telehealth companies over the marketing of compounded GLP-1 products, citing claims that implied sameness with FDA-approved products and branding that implied the telehealth company was the compounder. FDA's June 15, 2026 guidance adds that compounded drugs must not be called generic versions of approved drugs and that no pharmacy is "FDA-approved". Compounded products are, by definition, compounded, not FDA-approved. A clinic that offers them says so wherever they are named, does not compare them to the branded drug, and does not make efficacy claims it cannot support. The same claims are LegitScript rejection reasons, so a page that would draw an FDA letter also blocks certification.
FDA dated 25 more letters to telehealth firms on June 8, 2026, over the same kind of website claims about compounded semaglutide and tirzepatide. Its September 18, 2026 letter to Empower Pharmacy, a 503A compounding pharmacy, said its tirzepatide with niacinamide and semaglutide with vitamin B12 blends "appear to be essentially copies" of FDA-approved products, so a clinic should not advertise the added vitamin as what makes its program different. MedScale writes "compounded, not FDA-approved" into every ad and page that names a compounded product.
How does a weight loss clinic's landing page affect its ad account?
A weight loss clinic's landing page can restrict the whole ad account. Both platforms read the destination as part of the ad, and Meta categorizes the data source by what the site is about. A page that lists medications with prices and a checkout is an online pharmacy in that reading, and the restriction that follows applies to conversion events across the account, which is why cost per consult climbs after a clinic "just added" a medication menu. The compliant structure puts the clinic and the supervised program first, medication detail second, candidacy and pricing framed the way the platforms allow, and a prescription-required statement, provider credentials and a results-vary line on every page an ad can land on. MedScale builds clinic landing pages in that order.
What does weight loss clinic creative need to pass review?
- Provider-to-camera explaining how the program works, who it is for and what the first month involves.
- Program and process imagery: the consultation, the intake, the clinic, the follow-up cadence.
- Brand-voice copy with the program as the subject. "The program includes weekly check-ins" passes; "struggling with your weight?" does not.
- Testimonials about the experience of care, not about physical change.
- Adults-only targeting set at the ad set, which MedScale checks before every launch.
Can a weight loss clinic advertise GLP-1 programs on TikTok?
Not for compounded GLP-1 products. TikTok's Healthcare and Pharmaceuticals policy, last updated September 2026, says prescription medicine ads in the United States may be allowed with proof of approval and certification from the FDA and 18+ targeting; most other markets do not allow them. Compounded semaglutide and tirzepatide are not FDA-approved, so they cannot meet that rule. TikTok stays a clinic awareness channel with provider-led content, or a channel for non-prescription offers, and rarely a direct-response channel for a GLP-1 program. MedScale runs TikTok for weight loss clinics on that awareness basis only.
How should a weight loss clinic without certification structure Google Search?
An in-person weight loss clinic without Google's certification still reaches strong local search demand, provided the campaign is built on the queries that are open. MedScale's page on Google Ads for weight loss clinics sets out how it builds those campaigns. Program intent ("medical weight loss program", "GLP-1 clinic"), supervision intent ("doctor supervised weight loss") and location intent ("weight loss clinic near me") run in separate ad groups with location-level budgets, and the ad text may now name the medication options. Search terms are reviewed weekly, and any drug-name query that Google matched to a program keyword is checked against the keyword rule, because targeting drug terms is the part that still needs certification. Drug-name searches the clinic cannot target are the organic team's job, not the paid account's.
Why do repeated disapprovals matter more than one rejected ad?
A rejected ad costs a day. A pattern of rejections in the same policy area costs the account, because repeated violations signal to Meta's systems that the advertiser is not operating within policy, and enforcement then extends beyond the ad to the account and to linked assets in the same business. Clinics rarely lose accounts to one egregious ad; they lose them to a third creative round that reintroduced the second-person hook, resubmitted twice, followed by a landing page update that added the medication menu. MedScale therefore tracks disapproval rate as a leading risk indicator, rewrites every rejection rather than re-filing it, and puts any change to the landing page through the same policy read as the ads.
How does the intake decide what a weight loss clinic's ad spend was worth?
A weight loss clinic's paid traffic is only as valuable as the intake it lands on. A qualification flow that asks the candidacy questions before the consult (age, state, history, contraindications, self-pay or insurance) filters out the people the prescriber cannot treat before a slot is booked, so clinicians are not paid to say no. MedScale builds the landing-page form to screen for candidacy before the consult. Every step of that flow fires a generic server-side event, and no third-party pixel reads a health field, so the booked consult rather than the form fill is what the campaign gets credit for. The clinics that report the best cost per consult are rarely the ones with the cleverest ads; they are the ones whose intake and tracking let the platforms optimize toward the right outcome.
How does MedScale run Meta and Google ads for medical weight loss clinics?
MedScale Health runs medical weight loss clinic acquisition as described on medscale.health/clinics/medical-weight-loss: search campaigns built on program and clinic intent, Meta creative pre-cleared against the health and personal attributes standards, landing pages whose form screens for candidacy before the consult, and server-side tracking on every step with no third-party pixel touching a health field. Where a clinic wants to keyword-target drug terms or promote the drug on Meta, the certification filings run alongside the campaigns.
Common questions
- 01Can a weight-loss clinic name semaglutide or Ozempic in its ads?
- Yes on Google, with limits: an in-person US clinic may name the drug in ad text and on its landing page without certification since October 29, 2025, but needs certification to keyword-target it; brand names also carry trademark risk. On Meta, an in-person-only clinic cannot promote a prescription drug, because Meta grants that authorization only to online pharmacies, telehealth providers and manufacturers, so leading with the program is the route.
- 02Why did our clinic's Meta account get restricted when we only advertise a service?
- Usually the site, not the ad. Meta categorizes advertisers by what the landing page looks like; a page that reads like an online pharmacy triggers the drugs standard and restricts conversion events. Page structure, pixel event names and the claims on the page all matter.
- 03Do we need LegitScript to run Google Ads for a weight-loss clinic?
- Not for an in-person clinic on program and clinic keywords, and not to name the drug in ad text or on the page. Keyword-targeting drug names needs Google's certification, and a clinic that prescribes by telehealth or ships medication needs LegitScript first, then Google's certification, before its ads serve.
- 04Can we say our compounded semaglutide is the same as Wegovy?
- No. Compounded products are not FDA-approved, and the FDA's 2026 warning letters to telehealth companies cited exactly that kind of sameness claim. State the compounded status plainly, avoid comparisons to branded drugs, and keep efficacy claims to what you can support.
- 05Is a weight-loss testimonial allowed in a Meta ad?
- Yes, for adults. Meta allows adults-only weight-loss ads to show a product's impact, and since July 22, 2026 it no longer bans before-and-after comparisons, so a testimonial about results is not banned on sight. It still cannot attack the person's prior appearance or promise a result in a set time without a qualifier, and under FTC guidance it has to reflect what customers can generally expect.
Sources
- 01Meta Advertising Standards: Health and wellnesschecked October 5, 2026
- 02Meta Advertising Standards: Privacy violations and personal attributeschecked October 5, 2026
- 03Meta Advertising Standards: Drugs and pharmaceuticalschecked October 5, 2026
- 04Google Ads policy: Restricted drug termschecked October 5, 2026
- 05Google Ads policy: Healthcare and medicineschecked October 5, 2026
- 06FDA press announcement: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1schecked October 5, 2026
- 07FDA warning letters database: 25 letters dated Jun 8, 2026, subject "False & Misleading Claims/Misbranded (Telehealth)"checked October 12, 2026
- 08FDA warning letter to Empower Clinic Services LLC dba Empower Pharmacy, MARCS-CMS 738238 (Sep 18, 2026)checked October 12, 2026
- 09FDA (Jun 15, 2026): FDA to telehealth companies, what to know when promoting compounded drugschecked October 5, 2026
- 10TikTok Ads policy: Healthcare and pharmaceuticalschecked November 3, 2026
- 11FTC: Health products compliance guidancechecked October 5, 2026
Related answers
Can You Advertise GLP-1 on Facebook and Instagram?
As of November 2026, GLP-1 telehealth brands can advertise on Facebook and Instagram to adults 18 and over if no copy implies the viewer's body or health; a prescription GLP-1 also needs LegitScript certification and Meta's authorization. MedScale, a paid ads agency for US telehealth brands and clinics, builds GLP-1 creative against those rules from the first concept, because accounts are lost to a pattern of disapprovals, not one banned claim. Since July 22, 2026, Meta judges before-and-after imagery by the claims around it.
Reviewed November 9, 2026
Can You Advertise GLP-1 on Google Ads?
As of October 2026, a GLP-1 telehealth brand can advertise on Google Ads once it holds LegitScript accreditation and Google's certification, which Google requires before prescription drug service ads serve in the United States. MedScale Health, a paid ads agency for US telehealth brands and clinics, sequences certification, then landing pages, then keywords. An in-person clinic may name semaglutide or tirzepatide in US ad text and landing pages without certification since October 29, 2025, but needs certification to keyword-target those terms.
Reviewed October 24, 2026
What Is Meta's Personal Attributes Policy and Why Does It Block Weight Loss Ads?
As of October 2026, Meta's Privacy Violations and Personal Attributes policy says “ads must not contain content that asserts or implies personal attributes,” and it names “physical or mental health (including medical conditions),” so weight loss copy about the reader's body fails. MedScale Health, a paid ads agency for US telehealth brands and clinics, checks every weight loss ad against that sentence before it spends and writes the creative in brand voice, so no line is about the viewer. Meta's change log shows the policy unchanged since June 2024.
Reviewed October 24, 2026
What Are the Rules for Advertising Compounded Semaglutide in 2026?
As of November 2026, compounded semaglutide can be advertised only on much narrower ground than during the shortage. MedScale Health, a paid ads agency for US telehealth brands and clinics, rewrites claims built on the shortage-era footing and labels compounded semaglutide as compounded, not FDA-approved. FDA resolved the semaglutide shortage on February 21, 2025, enforcement discretion ended in April and May 2025, and FDA's June 15, 2026 guidance tells telehealth companies not to present compounded drugs as generic, equivalent or FDA-approved.
Reviewed November 9, 2026
Last reviewed October 24, 2026. Platform policies change often; we re-verify every answer quarterly.